A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
Start Date
12/8/2025
Completion Date
8/1/2027
Summary
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Solbinsiran
Placebo
Conditions
Locations
Axsendo Clinical Research - Peak Heart & Vascular - Phoenix
Phoenix, Arizona 85014
United States
Synexus Clinical Research US, Inc./Orange Grove Family Practice
Tucson, Arizona 85741
United States
National Heart Institute
Beverly Hills, California 90211
United States
Ark Clinical Research
Long Beach, California 90815
United States
Catalina Research Institute, LLC
Montclair, California 91763
United States
Valley Clinical Trials, LLC dba Flourish Research
Northridge, California 91325
United States
CMR of Greater New Haven, LLC
Hamden, Connecticut 06517
United States
Northeast Research Institute - Downtown Office
Jacksonville, Florida 32204
United States
Novera Clinical Research
Miami, Florida 33135
United States
Inpatient Research Clinic
Miami Lakes, Florida 33014
United States
Clinical Site Partners, LLC dba Flourish Research
Winter Park, Florida 32789
United States
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois 60640
United States
Investigators Research Group
Brownsburg, Indiana 46112
United States
Saint Elizabeth Healthcare - Saint Elizabeth Covington Hospital
Covington, Kentucky 41011
United States
Flourish Research - Bowie
Bowie, Maryland 20715
United States
University of Massachusetts Chan Medical School
Worcester, Massachusetts 01655
United States
AB Clinical Trials
Las Vegas, Nevada 89119
United States
Clinical Research of Philadelphia
Pennington, New Jersey 08534
United States
Weill Cornell Medical College
New York, New York 10021
United States
Icahn School of Medicine at Mount Sinai
New York, New York 10029
United States
Cardiovascular Specialists of Willowbrook
Houston, Texas 77070
United States
Southern Endocrinology Associates
Mesquite, Texas 75149
United States
American Research Corporation at Texas Liver Institute
San Antonio, Texas 78215
United States
Endeavor Clinical Trials
San Antonio, Texas 78240
United States
Stroobants Cardiovascular Center
Lynchburg, Virginia 24501
United States
TPMG (Tidewater Physicians Multispecialty Group) Clinical Research
Newport News, Virginia 23606
United States
Carilion Clinic
Roanoke, Virginia 24014
United States
Eastside Research Associates
Redmond, Washington 98052
United States
UW Medicine Diabetes Institute
Seattle, Washington 98109
United States
Ecogene-21
Chicoutimi, G7H 7K9
Canada
C.I.C. Mauricie inc.
Trois-Rivières, G8T 7A1
Canada
ARC Biosystems
Vancouver, V6Z 2H2
Canada
Peking University Third Hospital
Beijing, 100091
China
Sichuan Provincial People's Hospital
Chengdu, 610072
China
Guangdong Provincial People's Hospital
Guangzhou, 510000
China
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang Shi, 471003
China
Zhongshan Hospital,Fudan University
Shanghai, 200032
China
The Affiliated Hospital of Xuzhou Medical College
Xuzhou, 221006
China
The Institute of Medical Science, Asahi Life Foundation
Chūōku, 103-0002
Japan
Takai Internal Medicine Clinic
Kamakura-shi, 247-0056
Japan
Medical Corporation Heishinkai OCROM Clinic
Suita-shi, 565-0853
Japan